CORHealthcare · Medical DistributionThe 14 Wall Street analysts covering Cencora, Inc. hold a median 12-month price target of $365 — +9.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 10 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Cencora, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
The bullish and bearish analyst opinions on COR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $382 → $390 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $342 → $346 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $330 → $350 |
| 6 Aug 2026 | UBS | Maintains | Buy | $412 → $430 |
| 24 June 2026 | B of A Securities | Maintains | Neutral | — |
| 24 June 2026 | B of A Securities | Maintains | Neutral | $280 → $285 |
| 10 June 2026 | Barclays | Maintains | Overweight | — |
| 11 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 7 May 2026 | UBS | Maintains | Buy | — |
| 28 Apr 2026 | William Blair | Initiates | Market Perform | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Feb 2026 | Barclays | Maintains | Overweight | — |
| 10 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 10 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 29 Jan 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 22 Jan 2026 | Jefferies | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 34% of US stocks
Cheaper than 93% of US stocks
Cheaper than 5% of US stocks
Cheaper than 29% of US stocks
Higher than 39% of US stocks
Higher than 50% of US stocks
Higher than 6% of US stocks
Higher than 48% of US stocks
Higher than 49% of US stocks
Higher than 96% of US stocks
Higher than 69% of US stocks
Higher than 16% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| CORCencora, Inc. | $62.3B | 71 |
| CAHCardinal Health, Inc. | $56.3B | 94 |
| MCKMcKesson Corp. | $103.0B | 87 |
| HSICHenry Schein, Inc. | $10.1B | 23 |
| CIThe Cigna Group* | $73.6B | 70 |
| BSXBoston Scientific Corp.* | $74.8B | 57 |
| EWEdwards Lifesciences Corp.* | $53.0B | 91 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
The rank is the raw material. Whether the rules would actually own Cencora, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted Cencora (COR) as a top momentum stock for long-term investors using its Style Scores system.
Why it matters — COR watchers would note that the stock is being identified by a well-known research platform as having strong momentum characteristics that could appeal to growth-oriented investors.
Cencora (COR) was highlighted by Zacks Investment Research as a strong growth stock. The piece notes that Zacks Style Scores offers investors a way to find top-rated stocks based on their investing style, and suggests why readers should take advantage of this tool.
Why it matters — A COR watcher would care because the item signals that the stock is being recognized as a growth candidate by an investment-research provider, potentially drawing more investor attention.
In its Q2 2026 performance update, the Allspring Growth Fund reported outperforming the Russell 3000 Growth Index, with Sandisk Corp. benefiting from the AI storage super-cycle. However, the update noted that shares of Cencora could not distribute in a 'risk-on' market.
Why it matters — A COR watcher would care because the fund commentary indicates Cencora shares faced headwinds distributing in a risk-on market environment.
Cencora reported fiscal 2026 third-quarter results featuring double-digit adjusted operating income growth, momentum in its specialty business, and $1 billion in share repurchases. The company also raised its full-year adjusted earnings outlook.
Why it matters — A COR watcher would care because the results show operational growth and an improved full-year earnings outlook for the pharmaceutical services company.
Cencora, Inc. released the transcript of its Q3 2026 earnings call, published by Seeking Alpha. The item consists of the earnings call transcript headline and source listing without additional content.
Why it matters — A COR watcher would care because the Q3 2026 earnings call transcript provides direct commentary from management on the company's latest quarterly results and outlook.
The 14 Wall Street analysts covering Cencora, Inc. have a median 12-month price target of $365, with estimates ranging from $330 to $430. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Cencora, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cencora, Inc. 71 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Aug 2026, Cencora, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +9.3% from the last close, and Ticker Nerd's factor model ranks Cencora, Inc. 71 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cencora, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $330 to $430 over the next 12 months.
Cencora, Inc. returned +15.7% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Cencora, Inc. is a global pharmaceutical solutions organization that serves as a critical link between drug manufacturers, healthcare providers, pharmacies, and patients.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Why Cencora (COR) is a Top Momentum Stock for the Long-Term". Zacks Investment Research highlighted Cencora (COR) as a top momentum stock for long-term investors using its Style Scores system.
Cencora, Inc. is a global pharmaceutical solutions organization that serves as a critical link between drug manufacturers, healthcare providers, pharmacies, and patients. Headquartered in Conshohocken, Pennsylvania, Cencora focuses on sourcing and distributing branded, generic, and specialty pharmaceutical products, along with over-the-counter healthcare items and related medical supplies. The company plays a central role in the healthcare supply chain by providing secure, reliable distribution and logistics services, as well as commercialization support for brand and specialty therapies. Beyond distribution, Cencora offers consulting, technology, analytics, and market access solutions designed to enhance provider efficiency and support patient access to complex treatments. Its operations span human and animal health, reflecting a broad presence across hospitals, health systems, community practices, specialty pharmacies, and veterinary channels. Today, Cencora is recognized as a leading partner for pharmaceutical innovators and healthcare organizations, helping ensure that therapies can reach the right patients in numerous markets worldwide.
CEO Dr. Robert P. Mauch Ph.D., PharmD · 47,000 employees · United States · https://www.cencora.com